 - Patients who have previously received M1 agonists or cholinesterase inhibitors tacrine, donepezil, metrifonate, rivastigmine for treatment of Alzheimers disease, no matter if approved or experimental can be included in this trial provided there was at least a washout period of 60 days prior to the screening assessments 